Welcome! Login | Register
 

Flu Vaccination Campaign to Kick-Off at RI State House—Rhode Island’s flu vaccination campaign will kick off…

Narragansett Beer Re-Releases Autocrat Coffee Milk Stout—Originally introduced last December as “Hi Neighbor Mash-Up,”…

RWU and Silent Witness Initiative To Launch Domestic Violence Online Database Tool—Roger Williams University and the Silent Witness Initiative…

Taco Pledges $400,000 to Support URI’s College of Engineering and Yes on 4—The Taco White Family Foundation will donate $400,000…

Rhody Ramble’s Upcoming Fall Events for Families—Rhody Ramble, launched in 2012, connects families with…

The Scoop: Kilmartin Hits Back at Hodgson, Harrop Urges Right-To-Work Municipal Ordinance, and More—Welcome back to The Scoop, the 4 p.m.…

Pawtucket Hall of Fame Taps Nesselbush As “Person of the Year”—Three City residents, Joan Crawley, former Director of…

Patriots Blown Out By Chiefs In Kansas City—Many billed the Patriots and Kansas City Chiefs…

NEW: Hodgson Blasts Kilmartin For No Bid Legal Contracts to State Legislator—Rhode Island State Senator Dawson Hodgson blasted Attorney…

Russell Moore: The GOP’s Curious Case of Catherine Taylor—Like most, this election year looks like it…

 
 

Kent Hospital Joins Worldwide Stroke Research

Friday, January 06, 2012

 

A medical way to halt the devastation of stroke.

Kent Hospital will join 80 hospitals worldwide in a major clinical trial that seeks to help people suffering from a stroke. This highly sophisticated study will evaluate the effectiveness of the new clot-dissolving drug Desmoteplase that may provide positive benefits to patients who have recently suffered a stroke. The advantage of Desmoteplase is that it may provide benefits up to nine hours after the onset of stroke symptoms, substantially longer than the currently used clot-dissolving drug, tissue plasminogen activator (TPA).

Stopping the damage of stroke

Most strokes are caused by a blood clot that blocks the flow of blood to the brain, depriving it of oxygen. Desmoteplase helps dissolve the clot thereby opening the blood vessel to restore blood flow. The local hub of this international trial is The Massachusetts General Hospital in Boston.

"This international multicenter ischemic stroke clinical trial evaluates the effectiveness of a new clot busting medication that can be given up to nine hours after the onset of stroke symptoms,” says Kent Hospital neurologist, Dr. S.M. Arshad Iqbal, MD. “We are excited about the potential of such treatment. If successful, a larger number of patients will be able to benefit, resulting in decreased disability from their stroke." 

Kent's leadership

“Taking part in this trial is extremely important and beneficial to the many stroke patients we see every year at Kent Hospital,” says Sandra Coletta, president and CEO of Kent Hospital. “Our participation shows the leadership we take as distinctive, 24-hour stroke center, in seeking the latest treatments to significantly improve outcomes for stroke patients.”

According to the American Heart Association/American Stroke Association, stroke is the fourth leading cause of death in the United States and the leading cause of serious, long-term disability.  On average, someone suffers a stroke every 45 seconds; someone dies of a stroke every three minutes; and nearly 800,000 people suffer a new or recurrent stroke each year.

For more health coverage, don't miss GoLocalTV, fresh every day at 4pm and on demand 24/7, here.

 

Related Articles

 

Enjoy this post? Share it with others.